New Data Suggests J. & J. Vaccine Works Against Delta


According to data from a clinical trial in South Africa, a single dose Covid-19 vaccine made by Johnson & Johnson is highly effective in preventing serious illness and death from Delta and Beta variants of the coronavirus.

The study is the first real-world test of the vaccine’s effectiveness against Delta, a highly contagious variant of the virus that has spread in the United States and much of the world. The South African Ministry of Health reported these preliminary results at a press conference on Friday. The data has not yet undergone peer-reviewed or published in a scientific journal.

At the trial, it was called SisonkeResearchers evaluated a dose of Johnson & Johnson vaccine in nearly 500,000 healthcare workers at high risk of COVID-19. The researchers reported that the vaccine had an efficacy of up to 95 percent against death from the Delta variant and 71 percent against hospitalization. (The vaccine did slightly worse against the Beta variant, which is thought to be more adept at circumventing the immune response than Delta.)

Co-chairman and director of the study, Dr. “We believe this vaccine does what it was designed to do to stop people from going to the hospital and dying in the intensive care unit,” said Linda-Gail Bekker. Desmond Tutu HIV Center at the University of Cape Town.

The results show that people who have received a dose of Johnson & Johnson vaccine do not need a dose of the vaccine. additional insignia, said Dr. Bekker.

When the study called breakthrough infections in vaccinated volunteers, it produced mild symptoms in 96 percent of cases and resulted in serious illness or death in less than 0.05 percent. The trial lasted from February to May of this year.

The results should reassure the millions of people receiving the Johnson & Johnson vaccine, especially since some previous studies have suggested that the single vaccine may be vulnerable to Delta. laboratory studies performance of the vaccine against the variant mixed upand a trial comparing one- and two-dose regimens has yet to report results.

Given the uncertainty, some Johnson & Johnson buyers asked for a second dose on their own. Health officials in San Francisco have issued an additional supplement to Johnson & Johnson-vaccinated residents. Pfizer-BioNTech or Moderna dosage vaccines.

South Africa Johnson & Johnson approves vaccine in April. The country struggled with an increase in the Beta variant of the virus earlier this year, but Delta has become the dominant variant in recent weeks. More than 8 million South Africans have received the Johnson & Johnson vaccine or at least one dose of the Pfizer vaccine.

virologist who led some studies for J. & J. at the Beth Israel Deaconess Medical Center in Boston. “This study was conducted as a real-world efficacy study in one of the most challenging epidemiological settings,” said Dan Barouch. did not attend the hearing. “This is very good news for the fight against the global Covid-19 pandemic,” he said.

South African researchers recorded two rare cases of coagulation disorders associated with the Johnson & Johnson vaccine in the trial; both participants made a full recovery.


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *